According to the latest documents disclosed by the U.S. Securities and Exchange Commission (SEC), Amphastar Pharmaceuticals Inc has signed a five-year supply agreement, under which all payments will be settled in RMB.

This agreement not only highlights the solid intention of long-term cooperation between both parties, but also reflects the gradual expansion of RMB settlement methods in cross-border trade. Direct settlement in local currency helps enterprises avoid exchange rate fluctuation risks and may improve transaction efficiency. This five-year cooperation framework provides visibility for Amphastar Pharmaceuticals' future revenue stability, while also demonstrating the company's strategic considerations in its international business layout.